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Abstract 
Carbon nanotubes (CNTs) have long been regarded as promising carriers in 
biomedicine. Due to their high surface area and unique needle-like structure, CNTs 
are uniquely equipped to carry therapeutic molecules across biological membranes 
and, therefore, have been widely researched for use in theranostic applications. The 
attractive properties of the CNTs entice also their use in the brain environment. 
Cutting edge brain-specific therapies, capable of circumventing the physical and 
biochemical blockage of the blood-brain barrier, could be a precious tool to tackle 
brain disorders. With an increasing number of applications and expanding 
production, the effects of direct and indirect exposure to CNTs on cellular and 
molecular levels and more globally the general health, must be carefully assessed 
and limited.  
In this chapter, we review the most recent trends on the development and 
application of CNT-based nanotechnologies, with a particular focus on the carrier 
properties, cell internalization and processing, and mechanisms involved in cell 
toxicity. Novel approaches for CNT-based systemic therapeutic brain delivery 
following intravenous administration are also reviewed. Moreover, we highlight 
fundamental questions that should be addressed in future research involving CNTs, 
aiming at achieving its safe introduction into the clinics. 
 
Keywords  
Carbon nanotubes (CNTs), functionalisation, biocompatibility, cell toxicity, blood-
brain barrier (BBB), brain delivery. 
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1. Introduction  
Carbon nanotubes (CNTs) are defined as cylindrical nanomaterials composed of a 
continuous, unbroken hexagonal mesh of carbon atoms. The first observation of 
CNTs by electron microscopy, credited to Iijima in 1991, opened a plethora of 
applications for this material [1]. This included high-strength composites, energy 
storage, field emission device, but also the use of CNTs for biomedical 
applications [2]. In particular, CNT ability to cross efficiently cell membranes and 
carry large amount of molecules has encouraged the design of nanotube-based 
delivery systems [3, 4].  
The concept of drug delivery was probably introduced by Paul Ehrlich, in 1897, 
when he theoreticized the use of “zauberkugeln” (in English “magic bullets”) 
intending to improve the efficacy of available therapeutics [5]. Long after this 
statement, delivery of therapeutic and imaging agents into specific organs or tissues 
has remained a promising approach to modulate the pharmacokinetics and 
bioavailability of therapeutics, and provide controlled release kinetics at a target site. 
Numerous materials with sizes between 10 to 1000 nm have been investigated, 
including liposomes, dendrimers, nanoemulsions, nanoparticles, quantum dots and 
CNTs. With their needle-like shape, CNTs display singular physico-chemical 
properties. Their large surface area, ranging from 50 to 1315 m
2
/g, allows the 
conjugation with extensive amount of therapeutic and imaging molecules [6-8]. 
Moreover, the high CNT length-to-diameter ratio enables them to efficiently 
penetrate biological membranes and accumulate into intracellular compartments [9]. 
Consequently, attachment of molecules to CNTs helps overcoming several 
administration problems, including insolubility, poor biodistribution and inability of 
therapeutic or diagnostic molecules to cross cellular barriers [3].  
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Despite their undeniable potential, concerns have emerged regarding the toxicity 
of CNTs, as various reports showed that pristine nanotubes could induce biological 
damage [10]. Excessive nanotube length, the presence of impurities from the 
synthesis process and the introduction of carboxylic groups at the CNT surface could 
trigger unattended and detrimental cellular responses [11]. Such parameters must 
therefore be thoroughly controlled and characterised to design safe and 
biocompatible nanotubes applicable as delivery systems. The post-synthesis surface 
modification of nanotubes with hydrophilic molecules, named functionalisation, has 
been reported as an efficient approach to enhance their water dispersibility and 
reduce their toxicity [12, 13]. This can be performed by covalently attaching 
moieties at the surface of CNTs or by non-covalent interactions between nanotube 
surface and hydrophobic/aromatic regions of amphiphilic molecules [14].  
To tailor nanotube function, therapeutic molecules or imaging probes can be 
added to functionalised CNTs (ƒ-CNTs) side-walls [4]. By taking advantage of their 
inner cavity, ƒ-CNTs can also be filled to keep the surface available for further 
modifications [15]. Contrast agents can be combined to nanotubes to generate CNT-
based hybrids with clinical imaging capabilities [16]. If such hybrids display 
desirable targeting capabilities, they become versatile imaging tools for diagnostic 
applications [17, 18]. CNT hybrids can also help tracking administrated nanocarriers 
to assess in real-time their spatial distribution and therefore measure their 
biodistribution profile [19]. The major medical imaging techniques, namely 
ultrasound, nuclear and magnetic resonance imaging (MRI), display limitation in 
terms of sensitivity or image resolution. To improve this, the combination of 
synergistic imaging modalities in a single carrier, such as CNTs, could be 
particularly valuable [20]. Beyond the promising properties of CNT-based hybrids 
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for multi-imaging capabilities, their dimensions need to be optimised in order to 
control their intrinsic imaging properties, improve their accumulation in target cells 
and enhance their biocompatibility profile. This dimension refinement is essential to 
demonstrate the potential of CNT-based hybrids and confirm their safety before 
conducting clinical studies.   
A wide range of studies have also reported on the development of carbon 
nanotubes for brain delivery, with results showing that adequate functionalisation is 
essential to produce biocompatible CNTs capable of local or systemic delivery of 
therapeutics to brain cells [21].  
In this review, a description of the physico-chemical properties and surface 
modification of CNTs needed for delivery will be presented. Moreover, the 
interaction between CNTs and mammalian cells will then be described, followed by 
a summary of their toxicity. Finally, we will look into the most recent advances 
involving CNT-mediated systemic brain delivery and in situ CNT biodegradation. 
2. Physico-chemical properties and surface modification of CNTs for 
biomedical applications 
2.1 Synthesis, classification and properties  
 
Carbon nanotubes can be generated by electric arc discharge and laser ablation 
using vaporisation of graphite target [22, 23]. Alternatively, they are synthesised by 
chemical vapour deposition which rely on the passage of carbon-containing vapours 
in a furnace containing metal catalysts [24]. CNTs can be classified as single-walled 
(SWNT) or multi-walled (MWNT) nanotubes, in accordance with the number layers 
that compose a single nanotube (Figure 1).  
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Figure 1. Schematic representation of single-walled (SWNT) and multi-walled 
(MWNT) CNTs. Single and multi-walled CNTs have similar structures but different 
diameter. The figure was redrawn and modified from [25] and [26]. 
SWNT and MWNT exhibit a diameter of 0.4-2 nm and 10-100 nm, respectively 
[26]. Both types are utilised as delivery systems and display large aspect ratios with 
lengths ranging from 50 nm to several microns. The length and diameter can be 
tuned by controlling the production conditions, but the design of CNT-based 
delivery systems require further post-synthesis shortening procedures to increase 
their biocompatibility and bioavailability [10, 19]. A reduction in the CNT length to 
diameter ratio can be achieved by strong acid treatment, ultrasonication, steam-
purification and mechanical methods [27-29].  
The unique physicochemical properties of CNTs, namely high surface area and 
length-to-diameter ratio, optimal electrical conductivity, and thermo-chemical 
stability, make them particularly attractive for biomedical applications [30]. 
However, pristine CNTs must be functionalised to improve their hydrophilicity and 
biocompatibility.  
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2.2 Non-covalent functionalisation 
 
The delocalised aromatic system of nanotubes layers makes them aggregate in 
bundles and results in their poor dispersibility in physiological aqueous environment 
[31]. The large surface area of CNTs enables non-covalent or covalent conjugation 
of hydrophilic molecules to enhance their dispersibility [13]. The non-covalent 
modification consists in the physical adsorption of amphiphilic surfactant molecules 
onto the surface of the CNTs by Van der Waals interaction, π-π stacking or 
electrostatic interaction [32-34]. The main advantages of this approach are the 
preservation of the intrinsic optical properties of CNTs and the simplicity of the 
functionalisation procedure [30]. However, the interaction after coating should be 
limitedly affected by presence of salt to maintain the stability of the complex in a 
physiological environment. Biocompatible polymers (e.g. Pluronic
®
 F-127, 
polyethylene glycol (PEG)) [35, 36], gum arabic [37], single-stranded DNA 
(ssDNA) [38] and proteins (e.g. bovine serum albumin, BSA) [39, 40] were reported 
to increase the dispersibility of CNTs.  
2.3 Covalent functionalisation 
 
Covalent CNT functionalisation relies on the chemical bound of functional groups 
to the wall of CNTs, and is also referred as chemical functionalisation [41]. In 
contrast to the non-covalent approach, chemical functionalisation leads to strong and 
stable chemical bonds grafted onto the sp
2
 carbon framework of the tips and sidewall 
of CNTs [42]. The functionalisation of CNT can be carried out by oxidation under 
strong acidic conditions, which produces carboxylic acid groups and shortening of 
CNTs [43]. However, the introduction of carboxylic groups at the surface of CNTs 
has been associated with cellular toxicity [28, 44]. Further reactions can conjugate 
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carboxylic acid groups to an amine or alcohol groups to obtain amide or ester 
linkage, respectively [13]. In addition to oxidation, another common chemical 
reaction is the 1,3-dipolar cyclo-addition using the condensation of an amino acid 
and an aldehyde [45].  
Both covalent and non-covalent functionalisations have shown their ability to 
increase the dispersibility of nanotubes in a physiological environment, making them 
available to cross cell membranes and accumulate into intracellular compartments.   
3. Uptake and cellular fate of functionalised CNTs (ƒ-CNTs) in 
cancer cells and macrophages 
Efficient uptake properties of CNTs have encouraged their use as drug delivery 
systems. After crossing the plasma membrane, the intracellular pathways of CNTs 
can lead to organelle accumulation and/or nanotube elimination [46-50]. The 
characterisation of their mechanisms of uptake and elimination remains of great 
interest to shape the delivery properties of CNTs and ensure their bio-clearance. 
3.1 Passive versus active mechanism 
 
A leading study by Pantarroto and collaborators demonstrated that the high aspect 
ratio of CNTs allowed them to efficiently cross cellular membranes [9]. 
Subsequently, a dual mechanism of uptake into mammalian cells has been described 
[51]: CNTs were shown to use either an endocytic pathway or the passive diffusion 
to penetrate through cellular membranes (Figure 2). In the endocytic mechanism, 
CNTs are internalised inside vesicles, named endosomes, before being directed to 
the lysosomes localised in the perinuclear compartment [52]. The energy-dependent 
uptake of nanotubes was described as predominantly clathrin-dependent for both 
SWNT and MWNT [53, 54]. Kang and colleagues showed that SWNT / doxorubicin 
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complexes, conjugated via hydrophobic π stacking, were internalised using the 
endocytic pathway and accumulated into the perinuclear lysosomal compartment of 
endothelial progenitor cells [49]. Whilst SWNT remained entrapped into lysosomes, 
DOX detached in the acidic lysosomal environment due to the pH-dependent π-π 
stacking interaction, diffused into the cytoplasm and reached the nuclear 
compartment to induce cell killing.  
In contrast, the passive diffusion of CNTs, also called needle-like penetration, 
results in the simple diffusion of CNTs through the cellular membrane without need 
of energy consumption [9, 55]. Following computational and electron microscopy 
studies, the passive diffusion of ƒ-CNTs through the phospholipid bilayer 
membrane, has been broken down in three steps: i) landing and floating of the 
ƒ-CNTs on the membrane surface; ii) penetration of the lipid head groups; and 
iii) sliding through the lipid tails (Figure 2) [56, 57].  
Figure 2. Uptake and cellular fate of ƒ-CNTs in mammalian cells. The bundled 
MWNTs bind to cellular membranes and are then internalised into cells by 
endocytosis. In the endosomes, bundles release single MWNT, which penetrate 
through endosomal membranes and enter the cytosol. Alternatively, short and 
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individualised CNTs (i) land on the surface of the plasma membrane, (ii) penetrate 
the lipid head groups and finally (iii) slide through the lipid tails to passively diffuse 
through the cell membrane. Both residual bundled MWNT in endosomes and free 
MWNT in the cytosol are recruited into lysosomes. CNTs can be excreted by 
exocytosis (not shown) or in autophagic microvesicles in case of cellular stress. 
Another exit mechanism has been reported in polynuclear neutrophils and 
macrophages where nanotubes are digested enzymatically. CNTs are also able to 
enter organelles and the nucleus. The figure was redrawn and modified from [51]. 
A model explaining the differential mechanism of uptake between active and 
passive mechanisms has been proposed by Yan and co-workers [51]. Accordingly, 
CNT clusters would be internalised by an endocytic mechanism, whereas 
individualised nanotubes would enter the cell by membrane diffusion (Figure 2).  
Interestingly, despite the significant effort dedicated to the characterisation of 
CNT internalisation pathways, there is no report suggesting that passive transport is 
preferred to endocytosis for drug delivery applications. However, one could indicate 
that both pathways support the versatile capabilities of CNTs to cross biological 
membranes.   
3.2 Differential uptake between non-phagocytic and phagocytic cells  
 
The use of CNTs for drug delivery entails their capture by macrophages, which 
participate in homeostasis and physiological defence mechanisms [58-60]. These 
cells are especially involved in the removal of external materials by phagocytosis, a 
cell endocytic pathway similar to endocytosis but involving the uptake of large 
particles (∼1 μm). Both endocytosis and phagocytosis are energy-dependent 
mechanisms that are impeded at low temperature [53]. Phagocytic cells take up 
CNTs mainly through phagocytosis but the blockade of this energy-dependent 
pathway still allows the uptake of CNTs by passive diffusion [61]. SWNT coated 
with phospholipid-polyethylene glycol (PL-PEG) were found to cross the cell 
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membrane of non-phagocytic cells (ASTC-a-1, COS7, MCF7, EVC304) by passive 
diffusion and accumulate into mitochondria, whereas in macrophages (RAW264.7), 
CNTs accumulated in lysosomes following a phagocytic mechanism [62]. These 
results suggest that the internalisation mechanism of nanotubes was not only 
dependent on the properties of CNTs but also on the phagocytic nature of cells. 
Within the same population of phagocytic cells (human monocyte-derived 
macrophages), a study intended to establish a differential uptake of fluorescently 
labelled nanotubes as function of their length [63]. Constructs above 400 nm in 
length were mainly localised in endocytic vesicular structures, while the fluorescent 
signal from shorter CNTs was more diffuse, supporting their extra-vesicular 
localisation in cell cytoplasm.  
Overall, these results suggest that shortening of CNTs enhances their passive 
diffusion uptake mechanism, even in phagocytic cells. 
3.3 Cellular fate of CNTs 
 
Following their passage through cellular membranes, CNTs were reported to 
accumulate in various subcellular compartments, such as the cell cytosol [61], 
endosomes [54, 64], the perinuclear region [65], mitochondria [62, 66] or the nucleus 
[51], according to their physicochemical properties and functionalisation. Exocytosis 
and biodegradation of CNTs have also been reported as possible cell elimination 
mechanisms for this material [46, 47, 50]. The description of such outcomes is 
crucial to confirm the potential of CNT bio-elimination, ultimately lowering the risk 
of CNT toxicity.  
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3.1.1 Exocytosis  
Taking advantage of the intrinsic CNT photoluminescence properties, SWNTs 
were tracked by Jin in real-time using single particle tracking, and showed similar 
endocytosis and exocytosis rate (Figure 2). [46, 47]. Using Raman spectroscopy 
mapping, Neves and colleagues found that oxidised and RNA-wrapped double-
walled CNTs (DWNTs) accumulated in cells over 3 h before being progressively 
released out of the cells over a 24 h period [67]. It recently emerged that the process 
of exocytosis could also be induced under stress conditions. Naive human monocyte 
macrophages and endothelial cells exposed to stress were able to release 
microvesicles containing CNTs [68]. This mechanism could eliminate exogenous 
and toxic carbon material by inducing the formation of autophagic microvesicles 
[69].  
3.1.2 Enzymatic degradation  
The enzymatic-based degradation of CNTs was reported as a possible mechanism 
by which cells eliminate this material (Figure 2). Studies by Allen and collaborators 
provided evidence of the degradation of oxidised SWNTs through enzymatic 
catalysis in abiotic conditions [70, 71]. Following the incubation of carboxylated 
SWNT with horseradish peroxidase in low H2O2 concentrations (40-80 μM), a 
combination of techniques including transmission electron microscopy (TEM), 
Raman and ultraviolet-visible-near-infrared (UV-NIR) spectroscopy, and showed 
that digested CNTs displayed reduced absorbance, dramatic length shortening and 
disappearance of their discriminating G- and D-bands. It was later proposed that the 
presence of carboxylic group and defects at the surface of CNTs are a prerequisite to 
trigger the interaction with the oxidative agent and that nanotube degradation was 
function of the defect density [72]. Using similar techniques, it was demonstrated 
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that in vitro exposure of SWNTs to neutrophils followed by enzymatic digestion 
with myeloperoxidase (MPO) promoted alterations in CNT structure [73, 74]. These 
findings were supported by in vivo studies using TEM, Raman spectroscopy and 
photoacoustic imaging, which showed degradation of SWNTs in lung tissue 
following pharyngeal administration in mice [48, 75]. Using TEM and Raman 
spectroscopy, our group also found evidence of SWNT degradation in mouse brain 
after stereotactic injection [76]. In a recent study, the amount of CO2 released from 
the enzymatic digestion of nanotubes in contact with horseradish peroxidase was 
measured, with a CNT degradation rate of ~0.002 % per day being reported, which 
corresponds to a half-life of ~80 years [77].  
While studies confirm that CNTs can be enzymatically degraded, the notion of 
degradation is still broadly employed and future reports must provide qualitative and 
quantitative data regarding the formation of by-products induced by CNT enzymatic 
degradation, especially for in vivo investigations.  
4. Biocompatibility of CNTs 
The toxicity of CNTs has been widely reported and is of major concern for human 
use [78]. It is accepted that CNTs are heterogeneous material with certain physico-
chemical properties that can promote deleterious biological responses [11]. 
Therefore, the use of CNTs, applied to the drug delivery field, requires the design of 
materials with enhanced biocompatibility properties to ensure the safe translation of 
this material into clinical use.  
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4.1 Main properties of CNTs influencing toxicity  
 
CNTs exhibit heterogeneous purity, length, type of functionalisation and surface 
interaction with plasma proteins that can affect their cellular toxicity. CNT toxicity 
mechanisms have been mostly explored by measuring cell viability, cell 
inflammation and the production of reactive oxygen species (ROS).  
The concept of cellular toxicity can be described using the Hierarchical Oxidative 
Stress Model associating the cell toxicity mechanisms with the intracellular levels of 
ROS [79] (Figure 3). At low concentrations, ROS can be neutralised by anti-
oxidants - e.g. glutathione (GSH), and detoxification enzymes. When the antioxidant 
defence is overwhelmed, further damages occur such as lipid peroxidation, change in 
cell morphology and genotoxicity [80, 81]. Excessive ROS production initiates an 
inflammatory response through the release of cytokines and chemokines [80, 82]. 
Finally, further ROS production induces the release of apoptotic factors leading to 
cell death [83]. The measurement of such end points relies more frequently on the 
quantification of cell metabolism, DNA content, membrane disruption or cellular 
apoptosis induction [28, 84]. 
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Figure 3. Hierarchical Oxidative Stress Model. This model associates the cell 
toxicity mechanisms with the intracellular levels of ROS. The figure was re-drawn 
and modified from [85]. 
In vitro toxicity studies comparing physico-chemical properties of CNTs are 
summarised and classified in Table 1.   
Table 1: In vitro comparative studies of ƒ-CNTs toxicity. 
List of abbreviations in Table 1.1: AM: alveolar macrophages; ATII: primary human 
alveolar type-II epithelial cells; ATP: adenosine triphosphate; BAL: broncho-
alveolar lavage fluid; BCA: bicinchoninic acid assay; CHO: Chinese hamster ovary 
cells; CXCL-2: chemokine CX motif ligand 2; DPPC: 
dipalmitoylphosphatidylcholine; EthD-1: ethidium homodimer-1; gCNTs: grounded 
carbon nanotubes; GSH: glutathione; hprt: hypoxanthine-guanine 
phosphoribosyltransferase; LDH: lactate dehydrogenase; MTS: 3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium; MTT: 3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide; 
NLRP3: nucleotide-binding domain leucine-rich repeat and pyrin domain containing 
receptor 3; NO: nitric oxide; NT1: uncoated carbon nanotubes; NT2: carbon 
nanotubes coated with acid based polymer; NT3: carbon nanotubes coated with 
polystyrene-based polymer; RNS: reactive nitrogen species; SWNT-PEG: single-
walled carbon nanotubes functionalised with polyethylene glycol; TUNEL: terminal 
deoxynucleotidyl transferase dUTP nick end labelling; TT1: human alveolar type-I-
like epithelial cells; XTT: 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-
tetrazolium-5-carboxanilide; WST-1: 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-
tetrazolio]-1,3-benzene disulfonate; : increase; : decrease. 
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The main factors involved in CNT toxicity are reported hereafter: 
4.1.1 Impurities 
Catalyst remnants from the CNT synthesis, such as nickel (Ni), cobalt (Co), iron 
(Fe) and molybdenum (Mo), and amorphous carbon, localised at the surface of 
nanotubes or entrapped within the CNTs, can lead to oxidative stress, anti-oxidant 
depletion and a reduction in cell viability [86, 101, 102]. Several methods can be 
used to reduce the presence of impurities including high-temperature annealing, 
acidic treatment by reflux or steam-purification [101, 103, 104]. It has been 
demonstrated that CNTs free of catalyst metals and graphitic contaminants are 
unlikely to result in any inflammatory response or impairment of phagocytosis [105].  
4.1.2 Dimensions 
CNT length has been shown to greatly influence CNT toxicity. Extremely long 
CNTs (10–20 μm) displayed asbestos-like behaviour and long bioretention in  
peritoneal mesothelium [11]. When macrophages attempted to engulf long CNTs 
displaying larger dimension than the actual cell, it resulted in frustrated phagocytosis 
leading to formation of granuloma [106]. Such lengths are impractical for drug 
delivery and the shortening of CNTs has emerged as a logical requirement for 
biomedical applications. Following the same mechanism, MWNT of 2.4–10 μm 
length, coated with Pluronic
®
 F-127, exerted higher toxicity than shorter materials 
(0.4–1.4 μm) in a murine macrophage cell line, while shorter CNTs led to higher 
inflammatory response [93]. This opposite effect of CNT length on cell viability and 
inflammation suggested that the Hierarchical Oxidative Stress Model could not 
always be applied to characterise the toxicity of CNTs. Other studies reported 
disparities between the impact of CNTs on cell viability and inflammation/oxidative 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 22 
responses [97, 101, 107, 108]. The effect of nanotube diameter on cellular toxicity 
was described only in few studies and contradictory results were reported, thus 
limiting any statement about the influence of such parameter [109, 110].  
4.1.3 Defects 
Defects at the surface of nanotubes may be topological (e.g. ring shapes other 
than hexagon), sp
3
 hybridised carbon atoms, incomplete bonding defects, doping 
with elements other than carbon, as well as various functionalities at the surface 
[111]. Studies by Fenoglio and Muller established that the presence of defects at the 
surface of CNTs triggered acute pulmonary toxicity and genotoxicity [84, 112]. It 
was later reported that the shortening of CNTs by sample ultra-sonication using 
concentrated acid solution produced defects at the surface of the nanotubes, which 
were correlated with enhanced pro-inflammatory and pro-oxidative response [28]. 
Such report demonstrated that the shortening process could be associated with the 
formation of defects leading to inflammation and cytotoxicity. 
 Due to the heterogeneity of CNTs and the lack of data about CNT surface 
characterisation, the association between CNT toxicity and their physico-chemical 
properties can be puzzling. For example, Cheng and collaborators found that short 
MWNT (0.2 ± 0.1 μm) altered the development of zebrafish embryo, while long 
MWNT (0.8 ± 0.5 μm) showed reduced embryo-toxicity [113]. Although the authors 
concluded that nanotube length influenced the toxicity on embryos, the formation of 
defects at the surface of nanotubes induced by prolonged ultra-sonication in 
concentrated acid could just as well be responsible for the toxicity measured  [113].  
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4.1.4 Functionalisation 
Efficient dispersion resulting in individualised CNTs must be achieved for drug 
delivery applications in order to reduce the formation of CNT aggregates and 
increase their biodisponibility [19]. The type and degree of functionalisation tends to 
influence CNT toxicity. Surface functionalisation of nanotubes with carboxylic 
groups, using acid treatment, showed increased defect formation at the surface of 
CNTs adsorbing catalyst particles and generating free radicals [114]. Human 
neuroblastoma cells exposed to different concentration of oxidised MWNT showed  
dose-dependent decrease in cell viability [114]. In contrast, T-lymphocytes incubated 
with CNTs functionalised by 1,3-dipolar cyclo-addition — forming aminated 
nanotubes — did not increase the apoptotic proportion of immune cells and 
preserved their inflammatory functionality by maintaining their interleukin secretion 
following the activation by lipopolysaccharides (LPS) [12].  
4.1.5 Protein binding 
Protein binding to the surface of nanotubes occurs in a physiological 
environment, such as the blood circulation system, but can also be used as a strategy 
for CNT dispersion. The compact and multi-layer form of bovine fibrinogen (BFG) 
proteins was shown to reduce the toxicity of CNTs proportionally to the degree of 
adsorption onto the surface of nanotubes [115]. In contrast, Dutta and colleagues 
showed that MWNT dispersed in serum bovine albumin induced pulmonary fibrosis 
[116]. By coating the same material with Pluronic
®
 F-108, the amphiphilic polymer 
was able to protect the lysosomal membrane from CNT damage and abolish the 
formation of pulmonary fibrosis [116]. 
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4.2 Influence of cell model on CNT toxicity  
 
Recent studies have highlighted that the toxicity of nanotubes is not only 
dependent on their physico-chemical properties but also on the cellular model used 
for toxicity assessment. In a study by Foldbjerg and colleagues, epithelial cancer 
cells (A549), human monocyte-derived macrophages (THP-1) and mouse 
macrophages (J774) were exposed to SWNT dispersed in BSA. Incubation at 
10 µg/mL led to reduction in cell viability, necrosis, reduction of phagocytic ability, 
increased ROS levels and cytokine release in J774 cells, while A549 and THP-1 cells 
treated in the same conditions were not affected [117]. As J774 cells exhibited the 
highest phagocytic properties, the authors suggested that the toxicity of SWNT was 
mostly dependent on the uptake capacities of the cellular model used. However, the 
lack of inclusion of primary cells in this study could raise interrogations about the 
pertinence of such results in vivo. In a similar study, the toxicity profile of pristine 
MWNT of different length (0.6, 3 and 20 μm) was assessed in primary lung 
epithelial cells (TT1), primary human alveolar type-II epithelial cells (ATII) and 
primary lung alveolar macrophages (AM) [92]. Long MWNT led to an increase in 
lactate dehydrogenase (LDH) release, cell viability and cytokine secretion in AM 
cells, while shorter MWNT induced a stronger response in epithelial cells. In an 
interesting study by Asghar and colleagues, which focused on the toxicity of CNTs 
towards germline cells, no significant toxicity was found upon exposure of human 
sperm samples to 1-25 μg/mL of carboxylated SWNTs, although higher 
concentrations resulted in a significant increase in the production of reactive 
superoxide species [118]. 
The different response of epithelial and macrophage-like primary cells to CNTs 
highlights the need to select appropriate and relevant models to test in vitro the 
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toxicity of CNTs. In our opinion, epithelial cells, macrophages and cells from the 
reticuloendothelial system should be included in any studies aimed at assessing 
toxicity of CNT-based nanocarriers.    
4.3 Mechanisms of cellular toxicity triggered by CNTs 
 
The mechanisms of cellular toxicity induced by nanotubes have been essentially 
described using pristine CNTs and were mostly related to the production of oxygen 
radicals [50] (Figure 4).  
 
 
 
 
 
 
 
 
 
Figure 4. Molecular mechanisms induced by CNT uptake. Schematic 
representation of the main molecular and cellular responses associated with CNT 
internalisation by cells. Cell exposure to CNTs could have negative effects, namely 
oxidative stress which can promote inflammation, mitochondrial oxidation and 
activation of apoptosis, blocking of ion channels leading to loss of enzyme function 
and cytoskeleton interference imparting proliferation and migration. Effects reported 
as positive include activation of the complement system which promotes 
phagocytosis and biodegradation of the CNTs. 
 
The induction of oxidative stress activates signalling pathways mediating 
inflammation and, ultimately, to cellular toxicity. Activation of NF-κB or AP-1 
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transcription factors by CNTs has been directly involved in upregulating genes 
involved for the release of cytokines such as IL-1, IL-6 and TNF-α [50, 119]. CNT-
related oxidative stress could result in oxidation of mitochondrial phospholipids and 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidation leading to 
inflammation and apoptosis, but also positive outcomes such as CNT biodegradation 
in neutrophils [71, 120].  
Several non-oxidative stress-dependent effects were found related to the cellular 
accumulation of CNTs, such as the blocking of ion channels leading to loss of 
enzyme function, the interference with the cytoskeleton impacting proliferation, 
migration and phagocytosis, and the potential induction of a tumourigenic response 
[121-123]. It was reported that SWNT and DWNT could be responsible for 
activating the classical and alternate pathways of the complement system [124]. This 
was further associated with increased cellular infiltration and phagocytosis, as well 
as reduced pro-inflammatory cytokine secretion, thus supporting the beneficial effect 
of complement activation triggered by CNTs [125].   
4.4 In vivo toxicity studies in non-brain tissues after intravenous administration 
of CNTs 
A majority of pre-clinical toxicological studies assessed the toxicity of CNTs after 
pulmonary inhalation/exposure [10, 106]. However, drug delivery mediated by CNT 
carriers requires the study of their toxicity following intravenous (i.v.) 
administration. In most reports, this evaluation was done using histological analysis 
[58, 126, 127], blood cell counting [128] and inflammation detection [126, 127] in 
organs and blood. A summary of the studies reporting the toxicity of ƒ-CNTs in 
murine models is presented in Table 2. 
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Table 2: Representative in vivo studies of ƒ-MWNT and ƒ-SWNT injected IV in murine 
models 
List of abbreviations in Table 1.2: ALP: alkaline phosphatase; d: diameter; ƒ-MWNT: 
functionalised MWNT; GPCRs: G protein-coupled receptors; inj.: injection; 
ISL: isoliquiritigenin; L: length; NS: non-significant; RES: reticulo-endothelial system; 
: increase; : decrease. 
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Dispersion was shown to be a key factor influencing CNT toxicological effect. 
Indeed, purified pristine MWNT injected intravenously accumulated mainly in the 
lungs as large aggregates, causing short-term respiratory distress [58]. The 
intravenous injection of pristine MWNT was also shown to form large CNT 
aggregates in liver and lungs and induce inflammatory cell infiltration around the 
airways and blood vessels in lung tissue [127]. In contrast, the i.v. injection of 
purified SWNT dispersed in 1.0 % wt Tween
®
-80 in mice resulted in limited organ 
toxicity, despite large accumulation in liver, lung and spleen organs [133]. An 
increase in GSH level in liver and lungs suggested the induction of oxidative stress 
but the level of TNF-α in serum remained unchanged. In another study, SWNT 
covalently or non-covalently functionalised with PEG were injected i.v. in athymic 
mice. Histological and blood analysis of liver and spleen did not reveal any acute or 
chronic toxicity up to four months post administration [128], thus suggesting that  
attachment of appropriate functional groups at the surface of CNTs is a critical 
parameter to enhance their biocompatibility. More recently, toxicity of chemically 
functionalised MWNT to spleen was evaluated over 2 months, with no functional or 
histological modifications detected [126]. However, MWNT were shown to transfer 
from the red pulp to the white pulp over time, suggesting the formation of a splenic 
adaptive response.  
Overall, the induction of in vivo inflammatory responses by ƒ-CNTs is reduced 
but the persistence of such materials in major organs (i.e. lungs, liver and spleen) 
still requires further toxicological investigation. Moreover, there is currently no 
consensus about what animals models should be used to assess the short and long-
term impact of CNT exposure in biological tissues. It is important that clear 
guidelines are established by the scientific community, so that the results and their 
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interpretation/comparison are not affected by the different testing methods. 
Nevertheless, the results available to date suggest that i.v. injection of properly 
functionalized CNTs is well-tolerated and their use as carriers for therapeutic and 
imaging applications can be justified.    
5. CNTs as carriers for therapeutic brain delivery  
The delivery of therapeutic molecules to the brain is severely restricted by the 
presence of the blood-brain barrier (BBB), a complex network comprising brain 
endothelial cells, astrocytes and other support cells, that control the influx and efflux 
of nutrients and other molecules to the brain parenchyma. For this reason, treatment 
of complex neurodegenerative disorders and brain gliomas remains a challenge. 
When particle size is not small enough to overcome the BBB size restriction (i.e. 
<100 nm), nanoparticle-based brain-targeted therapeutic approaches have, thus far, 
taken advantage of the existing physiological mechanisms of transport to improve 
brain delivery. Polymer- and lipid-based nanoparticles are usually decorated with 
targeting moieties to support receptor-mediated transcytosis across the BBB. The 
capacity of CNTs to cross the BBB by both receptor- or adsorptive-mediated energy-
dependent pathways (transcytosis) and passive energy-independent mechanisms 
(needle-like crossing) constitutes a major advantage compared to other nanocarriers. 
In addition to the intrinsic ability to cross biological membranes, CNTs possess high 
surface area, which enables the loading and delivery of high doses of drugs to the 
therapeutic site, as well as intrinsic optical and thermal properties, with potential 
multimodal real-time tracking and photo-thermal applications. Although CNTs 
display optimal characteristics for use as nanocarriers in brain delivery, the intrinsic 
barrier-crossing capacity constitutes a limitation, due to unspecific bioaccumulation, 
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and therefore specific brain target is important to increase brain accumulation and 
reduce systemic side effects. 
5.1 Intracranial administration of CNT-based therapeutics  
 
Local administration of therapeutics could bypass the BBB restriction and allow 
effective therapeutic doses to be achieved in the diseased tissues. This approach 
could be relevant in certain brain disorders, such as tumours and stroke, in which 
initial surgical approach is often necessary. Scheme 1 highlights the main strategies 
involving local CNT-mediated therapeutic brain delivery. 
 
 
 
 
 
 
 
 
 
Scheme 1. Different stereotactically-delivered CNT-based strategies for brain 
therapy.  
 
The conjugation of immunostimulatory CpG oligonucleotides to SWNTs was 
shown by Zhao and collaborators to be beneficial for the treatment of glioma-bearing 
mice [137]. Increased uptake of SWNT-CpG by tumour-associated inflammatory 
cells was found after a single intracranial injection (compared to the free CpG), 
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which resulted in a strong anti-tumoural response, decreased tumour size and an 
increase in median animal survival time [137].  
Taking advantage of the capacity of CNTs to absorb NIR radiation and convert it 
to heat, Santos and colleagues used CNTs for photothermal-mediated brain tumour 
therapy. The authors showed that a combination of intratumoural SWNTs injection 
and NIR exposure in athymic GBM-bearing mice not only suppressed tumour 
growth compared to SWNTs or NIR per se, but also inhibited tumour recurrence for 
up to 80 days [138]. The electrical properties of CNTs prompted several research 
groups to use these carriers as scaffold for stem-cell mediated neuronal repair. 
Studies by Moon and colleagues in rats with stroke-induced brain injury revealed 
that focal injection of neural progenitor cell (NPC)-impregnated CNTs improved rat 
behaviour and reduced infarct cyst volume and area [139]. Similarly, pre-injection of 
amine-functionalised SWNTs onto the right lateral ventricle was shown to reduce the 
infarction area and improve behavioural functions following focal ischemic injury in 
rats [140]. The authors showed that the neuroprotective effect was achieved by 
reducing apoptosis, inflammation and glia activation and proposed that, even without 
NPCs, the high surface energy of the positively-charged SWNTs provided a 
favourable environment for neuronal regeneration. In a very recent study by Xue and 
colleagues, intraventricularly-injected aggregated SWNTs (aSWNTs) were shown to 
reduce methamphetamine (METH) addiction symptoms in mice by causing 
oxidation of METH-enhanced extracellular dopamine, which induced inhibition of 
the rewarding and psychomotor-stimulating effects of METH [141].     
A previous study from our group revealed that the local f-MWNT-mediated 
delivery of siRNAs targeting caspase-3 (siCas3) successfully prevented neuronal 
death in an endothelin-1 (ET-1) rat stroke model (Figure 5) [142]. This was 
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supported by observation of a decrease in apoptosis in the penumbra lesion (Figure 
5A-C) and a statistically significant improvement in the “skilled reaching” behaviour 
test (Figure 5D) for f-CNT:siCas3 treated rats, compared to animals receiving 
complexes of non-specific siRNA (siNEG) and f-CNT (f-CNT:siNEG) or siCas3 
alone.  
 
Figure 5. In vivo uptake and degradation of f-MWNTs by microglia after 
intracranial administration into mouse brain. (A-D) TEM images of brain 
sections showing microglia cells engulfing MWNT-NH3
+
 within phagosomes 48 h 
after injection (red squares). (B, D) High magnification TEM images showing clear 
loss of tubular structure of MWNT-NH3
+
 in some phagosomes of the microglia 
(shown in D) even within 48 h post-administration (adapted from [76]). (E-H) RNAi 
using f-CNT in vivo. (E) Dosage regimen of the siRNA and endothelin (ET-1) into 
C57Bl/6 mice and (F) TUNEL staining of the mouse brain cortex after injection of 
5% dextrose, f-CNT alone, siCaspase 3 alone, and the siCaspase3:f-CNT complexes, 
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followed by ET-1 injection. (G) The f-CNT: siCaspase3 group showed the least 
apoptosis quantitatively indicating effective and specific siRNA delivery in vivo 
compared to siRNA alone. (H) Behavioural analysis of rats after stroke induction in 
the all the treated groups using the skilled reaching test (adapted from [142]). 
 
While the intracranial delivery of drugs could be of clinical utility, its wide 
application is nevertheless limited by the invasiveness of the technique and patient 
compliance. The versatility of nanotubes and their unique mechanism of interaction 
with cells paved the way for researchers to explore the use of CNTs as carriers for 
systemic drug delivery to the brain. 
5.2 Systemic administration of CNT-based therapeutics 
 
The ability of CNTs to penetrate biological membranes without perturbing the 
membrane integrity prompted researchers to test CNTs as vehicles for systemic 
therapeutic delivery across the BBB. Early evidence of efficient BBB translocation 
by CNTs was provided by studies in primary brain endothelial cells [143-145] and 
other commonly used in vitro BBB models [146]. 
 
5.2.1 In vitro BBB translocation 
The interaction of f-MWNTs with the BBB has been previously investigated by our 
group using a BBB co-culture model comprised of primary porcine brain endothelial 
cells (PBEC) and primary rat astrocytes. This model replicates the physiological and 
biochemical features of the human BBB, including high trans-endothelial electric 
resistance (TEER), expression of membrane transporters and tight junction proteins 
[143]. TEM analysis revealed that f-MWNTs were quickly internalized (within 4h) 
by PBEC cells via endocytosis, with f-MWNTs being released from endocytic 
vesicles near the abluminal side of PBEC within 24-48 h (Figure 6) [144]. 
Moreover, Scanning TEM (STEM) showed that this process did not cause any 
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damage to the cell membrane (Figure 6). Since no involvement of the tight junctions 
was detected during translocation, it was suggested that f-MWNTs use a transcellular 
route to cross the BBB.  
In a subsequent study, the effect of CNT diameter on BBB translocation was 
investigated. Gamma counting was used to quantify the rate of translocation of 
“wide” (~35.9 nm diameter) (w-MWNTs) or “thin” (~9.2 nm) (t-MWNTs) f-
MWNTs across the PBEC co-culture model over a 72 h period. In general, higher 
percentage transport across PBEC was achieved for w-MWNTs compared with t-
MWNTs (~15.6% and 7.6% of total dose after 72 h, respectively) [145]. Targeting of 
f-MWNTs was  also tested in this study, in order to assess whether BBB 
translocation could be further improved. For this purpose, CNT synthesis was 
modified to incorporate a targeting peptide, angiopep-1 (ANG), to the carrier 
surface. This small peptide binds LRP1, a lipoprotein receptor that is overexpressed 
on brain endothelial cells of the BBB and several human tumours [147]. Indeed, 
higher values were obtained for ANG-functionalized w-MWNT and t-MWNTs 
(~20.3% and 11.6%, respectively) compared to the non-targeted carrier (~15.6% and 
7.6%) [145], using the in vitro PBEC co-culture model. This confirmed that 
conjugation of this small LRP1-targeting peptide to f-CNT, enhances BBB 
translocation and therefore could be of beneficial use for brain-targeted therapies. 
The capacity of CNTs to cross the BBB in vitro without compromising this 
barrier was also demonstrated by Shityakov and colleagues. The authors used phase-
contrast and fluorescence microscopy in combination with molecular dynamics 
simulation to demonstrate that amine-functionalized FITC-labelled MWNTs 
(MWCNT–NH3
+–FITC) were able to penetrate murine microvascular cerebral 
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endothelial (cEND) monolayers layers over a 48 h period, without compromising 
cell integrity [146]. 
 
 
Figure 6. Transcytosis of f-MWNTs across an in vitro BBB model. PBEC were 
incubated with MWNTs-NH3
+
 (20 µg/ml) for 4, 24 or 48 h. Cells were fixed in 2.5% 
glutaraldehyde for 24 h, before processing for imaging. (A) Bright field TEM and 
(B) low voltage STEM images of polyester filters showing the uptake and 
transcytosis of MWNTs-NH3
+
 across the PBEC monolayer. At 4h, MWNTs-NH3
+
 
clusters are seen interacting with the PBEC monolayer (or already within vesicles), 
while at 24 h the clusters appear within endocytic vesicles. At 48 h, the vesicles are 
seen partly opened towards the basal chamber to allow the release of vesicle 
contents. Scale bars: (A) 1 μm; inset: 500 nm. (B) 4 and 24h: 500 nm; 48 h: 400 nm. 
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BF: bright field; ADF: annular dark field; HAADF: high angular annular dark field. 
Figure reproduced from [144]. 
 
5.2.2 In vivo BBB crossing  
 
In addition to several in vitro studies, pre-clinical studies involving i.v. injection 
of CNTs provided unequivocal evidence of the capacity of CNTs to reach the tissues 
beyond the BBB. 
In one of our very first studies, aiming at determining the impact of f-MWNT 
diameter on systemic organ biodistribution, it was revealed that radiolabelled t-
MWNT conjugated to humanised IgG or fragment antigen binding region (Fab′) 
showed higher tissue affinity (including higher brain affinity) compared to w-
MWNTs [148]. In a subsequent study, designed to investigate in detail the brain 
uptake, accumulation and elimination of t- and w-MWNTs (with or without ANG 
conjugation), following systemic administration in healthy mice [145], higher brain 
uptake was also found for t-MWNT (~2.6% ID/g tissue at 5 min) compared to w-
MWNT (~1.1%) (Figure 7). Importantly, ANG brain targeting effect was significant 
for w-MWNT-ANG (~2.0% vs 1.1.%) but not for t-MWNT-ANG (~3.0% vs 2.6%). 
The capillary depletion method (which removes the vascular fraction of the brain), 
was then used to evaluate the f-MWNT content in the parenchyma and vascular brain 
fractions. Greater parenchyma uptake/accumulation was found for t-MWNTs 
compared to w-MWNTs, particularly at early times post-injection, while better 
parenchyma retention was found for w-MWNTs conjugates. Negative elimination 
rate constants (Kel), indicating parenchyma retention, were obtained for w-MWNT 
and w-MWNTs-ANG (Kel ~ -0.026 and -0.05, respectively), compared to t-MWNT 
and t-MWNT-ANG which exhibited positive Kel values (~ 0.034 and ~ 0.019) 
suggesting elimination from parenchyma.  
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Since LRP1 overexpression has been described not only on brain endothelial cells 
but also for malignant brain tumours [147], experiments were also performed to 
investigate the capacity of i.v. injected ANG-coupled w-MWNTs, which show 
higher brain parenchyma retention, to target this type of tumour. Interestingly, w-
MWNT-ANG not only showed significantly higher uptake in glioma when 
compared to normal brain, but also enhanced accumulation in glioma compared to 
the passively targeted w-MWNT [145], which suggests that ANG-coupling can 
provide a double-targeting effect, with improved brain and tumour uptake. 
Overall, although in vitro data suggested that wider f-MWNTs are more efficient 
in crossing the BBB, the available in vivo data suggests that uptake in healthy brain 
tissues after systemic injection is favoured by f-MWNTs with smaller diameter, 
while wider MWNT exhibits better brain retention. ANG conjugation enhances brain 
uptake of wider MWNTs but offers no advantage to brain uptake of thinner ones. 
ANG-modified f-MWNT, of wider diameter, seems to be the most suitable candidate 
among the ones studied, for BBB and brain tumour double-targeting. Since the BBB-
crossing studies were performed with “empty” CNTs, nevertheless, it is not known 
whether the % ID achieved is sufficient to generate a disease-specific response.  
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Figure 7: Uptake of radiolabelled f-MWNTs into murine brain after systemic 
administration. C57BL/6 mice were injected, via tail vein, with wide (w-MWNT) 
or thin (t-MWNT) MWNTs (50 μg, 0.5 MBq). After perfusion with heparine-
containing saline, brain accumulation was quantified by gamma scintigraphy, which 
was followed by capillary depletion at 5 min, 30 min, 1 h, 4 h and 24 h. The overall 
brain uptake of nontargeted and targeted (ANG-conjugated) (A) t-MWNTs or (B) w-
MWNTs, expressed as % injected dose per gram of brain (%ID/g), revealed higher 
uptake for t-MWNTs. The radioactivity of (D) t-MWNTs or (D) w-MWNTs in brain 
parenchyma and capillaries, measured after capillary depletion, was used to calculate 
the brain parenchyma/blood ratios. * p < 0.05; ** p < 0.01. Adapted from [145]. 
 
5.2.3 In vivo brain distribution   
 
Following the encouraging results where f-MWNT achieved reasonably high 
brain parenchyma accumulation when delivered systemically, we used multi-modal 
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imaging techniques to study in more detail the kinetics and spatial distribution of i.v. 
injected f-MWNTs in the brain [149]. SPECT/CT imaging clearly showed 
accumulation of radiolabelled t-MWNTs over the entire brain at the early time points 
after injection (5 min and 30 min), with higher radioactivity being detected in the 
mid-brain region (Figure 8A). Autoradiography of brain slices (2 mm thick), which 
allows greater spatial resolution via increased exposure times and support of semi-
quantitative analysis, provided further evidence of the preferential accumulation in 
the mid-brain region. Higher intensity was detected in sections of mid-brain (sections 
c3–5), while relatively lower radioactivity was detected in brain cortex (Figure 8B). 
Importantly, gamma counting and TEM (Figure 9A) showed preferential location of 
t-MWNTs in the brain capillaries up to 24 h after injection, which indicates that the 
MWNTs enter the brain via its endothelium. Moreover, TEM images showed that 
brain capillaries remained intact and circular, thus indicating that t-MWNT uptake 
into the brain was not caused by inflammation or the damage to the BBB.  
Taking advantage of its inherent optical properties, t-MWNTs were also directly 
imaged in brain sections and whole brain using state-of-the-art techniques, namely 
Raman and multi-photon luminescence microscopy (Figure 9B). The typical D 
(1309 cm
− 1
) and G (1599 cm
− 1
) MWNT Raman bands were seen in the spectra of 
capillaries (as well as in control bulk material), while no bands could be detected in 
whole brain sections. It is worth noting that t-MWNT accumulation in capillaries 
was ~ 4-fold higher than brain parenchyma. This highlights the limitation of this 
technique in terms of poor sensitivity. 
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Figure 8. Brain imaging after systemic administration of radiolabelled Fab’-
conjugated t-MWNTs. C57BL/6 mice were administered 50 μg/ml of 
[
111
In]MWNT-Fab’ via tail vein. (A) 3D reconstructed SPECT/CT images of mouse 
brains at 0–30 min, 4 h and 24 h post injection (0.5 MBq). (B) For autoradiography, 
brains were harvested at 5 min, 4 h or 24 h after i.v. injection (5–7 MBq) and 2 mm 
thick sections were prepared by coronal sectioning (from olfactory bulbs to 
brainstem). Sections were then analysed by autoradiography. Adapted from [149]. 
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Figure 9. Label-free brain imaging after systemic injection of Fab’-conjugated 
t-MWNTs. C57BL/6 mice were injected i.v. with MWNT-Fab′-DTPA (200 μg). (A) 
Five minutes after injection mice were perfused with 2.5% glutaraldehyde (in 0.1M 
cacodylate buffer), the brains were isolated and kept for another 24 h in fixation 
solution, before processing for TEM imaging. MWNT-Fab′-DTPA clusters are 
shown in the three different panels, including under higher magnification and 
enhanced contrast (middle panel, rectangular inlet). (B) For lifetime microscopy, the 
brains were isolated 1 h after injection (following perfusion with DiI and 4% PFA) 
and subsequently sectioned into 1 mm thick slices. Lifetime measurements are 
displayed below the multiphoton images (C, DiI; D, MWNT-Fab′-DTPA; E,  
position where both were present). Scale bar: 50 μm. Adapted from [149]. 
 
5.2.4 In vivo brain-targeted therapy 
While the above-mentioned studies investigated the BBB interaction, 
translocation and brain distribution of f-CNTs in vivo, they involved “empty” 
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carriers. To date, very few studies investigated the delivery of CNT-formulated 
drugs to the brain following systemic administration. 
Yang and colleagues used SWNTs for brain delivery of acetylcholine (ACh) to 
Alzheimer disease (AD)-bearing mice. In this regard, the administration of SWNTs-
Ach, via oral gavage, resulted in improved learning and memory capabilities 8h after 
treatment. Contrasting results were obtained in animals treated with empty SWNTs 
or the free Ach, in which no significant improvement was observed [150]. This study 
also highlighted the importance of the correct dosing of CNTs in brain-targeted 
therapies, as the mitochondria were shown to be affected by high concentrations of 
SWNTs. In a study by Ren and collaborators, PEGylated and carboxylated MWNTs 
(oxMWNT-PEG) modified with ANG were used as carrier to deliver doxorubicin to 
mouse brain. In addition to increased brain uptake of Dox-oxMWNT-PEG-ANG 
compared to Dox-oxMWNT-PEG or Dox per se after 1 to 6 h, the authors observed 
a substantial increase in survival of glioma-bearing animals treated with Dox-
oxMWNT-PEG-ANG, compared to the saline-treated group [151]. Since 
fluorescence non-quantitative imaging was used to evaluate the doxorubicin 
dispersion in the brain, the accumulation rate of Dox-oxMWNT-PEG-ANG could 
not be compared to other delivery systems. Intravenously-injected NIR-fluorescent 
PEG-conjugated SWNT sensors, developed by Iverson and colleagues, showed 
selective detection of local nitric oxide concentration in the brain, with a detection 
limit of 1 µM, with potential applications in sensing and therapy [152].  
Table 3 summarizes the main studies involving local and systemic administration 
of CNT-based carriers for brain delivery, including carrier modifications, disease 
model and stage of development.    
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 44 
Table 3. Representative studies involving local or systemic administration of 
CNT-based nanocarriers for brain delivery. 
List of abbreviations in Table 3: TMZ: temozolomide; SWNTs: single-walled carbon 
nanotubes; MWNTs: multi-walled carbon nanotubes; Ox-SWNT/MWNT: oxidized 
SWNT/MWNT; NIR: near infrared; NPCs: neural precursor cells; aSWNTs: 
aggregated SWNTs; METH: methamphetamine; NH3
+
-MWNTs: ammonium 
functionalized MWNTs; BBB: blood-brain barrier; Fab: fragment antigen binding 
region; ANG: angiopep1; w-MWNT: wide MWNT; t-MWNT: thin MWNT; AD: 
Alzheimer’s disease; DOX: doxorubicin; NO: nitric oxide;  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 45 
5.3 In vivo toxicity of CNTs in brain tissues 
 
Cell and macromolecule traffic into the brain is strictly controlled by a tight BBB, 
efflux transporters and the presence of immune cells (microglia), to ensure a proper 
microenvironment in which neurons can function. Exposure to CNTs could disturb 
this fragile balance and result in cytoxicity. No studies have yet assessed brain 
toxicity following systemic administration of CNTs. The evidence available, 
obtained from studies involving intracranial injection of nanotubes, suggests that 
surface functionalisation contributes to the cytotoxic outcome.  
In a study by Bardi and colleagues, neuron toxicity was not detected in mouse 
brain cortex after stereotactic micro-injection of Pluronic
®
 F-127 coated-MWNTs 
(MWNT:F127). Histological examination revealed small neuronal damaged near the 
injection site (due to the mechanical penetration of the brain) but no further damage 
was observed after 18 days [153].  In a previous manuscript from our group, it was 
shown that cortical stereotactic injection in mouse brain of MWNTs functionalised 
by 1,3-dipolar cycloaddition (MWNT-NH3
+
) resulted in lower inflammation 
compared to the oxidised carrier (ox-MWNTs-NH3
+
) [154]. Similar uptake levels of 
the compounds were found in astrocytes, microglia and neurons, but a significantly 
higher release of the pro-inflammatory cytokines TNF-α and IL-1β, as well as 
microglia activation, was detected after injection of ox-MWNTs-NH3
+
 compared to 
MWNTs-NH3
+
. A recent follow-up study revealed that microglia is involved in the 
cytotoxic response generated by ox-MWNTs in brain tissue. Exposure of ox-
MWNTs to neuronal cultures did not lead to detectable cytotoxicity (measured by 
the modified LDH assay), whereas significant cytotoxicity was found in mixed glial 
cultures isolated from striatum, but not from the frontal cortex. Striatum-derived 
mixed cultures contain a higher density of microglia, compared to the higher amount 
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of astrocytes in the frontal cortex, thus suggesting that microglia is responsible for 
the CNTs-induced cytotoxicity in brain tissue [155].  
5.4 Biodegradation of CNTs in brain tissues 
 
The biodegradation of CNTs by brain cells has been studied in vitro and in vivo. 
Strong evidence suggests that CNTs can be degraded within human brain tissue by 
human MPO and hydrogen peroxide (H2O2).  
Using Raman spectroscopy, Kagan and colleagues demonstrated that, in the 
presence of H2O2, MPO promoted SWNT biodegradation via generation of reactive 
hypochlorite radical intermediate species that oxidise parts of the CNT wall-structure 
[74]. Importantly, the presence of PEG (widely used to increase in vivo 
bioavailability) did not interfere with this process. Biodegradation of oxidised and 
PEG-coated SWNTs (SWNTs-PEG) was observed after incubation for 7 days with 
MPO, H2O2 and NaCl. Further testing, carried out ex vivo using human neutrophils 
(which secrete MPO along with other proteases) showed efficient SWNTs-PEG 
degradation after only 8 hours [74]. In a follow-up study, the biodegradation of 
SWNTs-PEG was proposed to occur in a two-step process, with the initial stripping 
of the PEG coating, mediated by secreted proteases, followed by SWNT degradation 
via surface defects [156]. Interestingly, PEG removal from the surface of SWNTs-
PEG after systemic administration in mice has been previously described, but no 
explanation was provided for the mechanism [157].  
In vivo data provides further evidence of the role of MPO on the CNT degradation 
in brain cells. Increased inflammation and lower SWNTs clearance rate were 
detected in MPO mouse knockouts following pharyngeal aspiration, compared to 
wild type animals [75]. An elegant study by Nunes and colleagues, which used 
electron microscopy to assess degradation of stereotactically-administered f-MWNTs 
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in mouse brain cortex, detected loss of cylindrical structure of f-MWNTs following 
internalisation into microglia [76]. The oxidative environment of the microglia, 
which contains MPO, peroxidases and other degradative enzymes, could be involved 
in the observed degradation.  
Overall, the high surface area of CNTs, intrinsic capacity to cross the BBB, 
controlled toxicity and degradability in the presence of MPO enzymes are 
encouraging properties/observations for future applications of CNTs in the brain.  
6. Concluding remarks and future perspectives 
The progress achieved on the synthesis, design and functionalization of carbon 
nanotubes has greatly contributed for the promising results obtained in in vitro and in 
vivo CNT-related studies. Surface modifications have improved carrier 
biocompatibility and targeting, while shortening CNT length improved 
pharmacokinetics and organ distribution. A wide range of in vitro studies has also 
revealed the mechanisms by which CNTs can lead to cell toxicity, including 
oxidative stress and mitochondrial dysfunction. Although a few studies have 
addressed the long-term biocompatibility and the effects of CNT accumulation in the 
human organs (namely the effects of pulmonary exposure) a higher number long-
term follow-up studies should aim at evaluating the long-term pharmacokinetics, 
organ accumulation, intracellular fate and possible cytotoxicity of intravenously-
injected CNTs.  The results of these studies will provide essential information about 
the behaviour of CNTs in complex physiological environment, allow the refinement 
of physicochemical and biocompatible properties and, ultimately, lead to the 
development of clinically-ready nanotube-based carriers. While research involving 
CNT-mediated therapeutic delivery to the brain has shown that biocompatible CNTs 
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can efficiently reach the brain, little information is available about the amount of 
therapeutic molecule needed to obtain a significant therapeutic benefit. Future work 
should therefore focus on determining effective therapeutic disease-specific dosage, 
improving brain delivery and clarifying the fate of CNTs with the different CNS 
tissues, in healthy and diseased brain. This information would be extremely helpful 
for the design/production of improved f-CNTs-based delivery systems that can, in 
the future, constitute primary options for efficient targeted brain therapy. 
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